公开(公告)号：US20230028660A1

公开(公告)日：2023-01-26

申请号：US17899297

申请日：2022-08-30

申请人： The University of Sydney

发明人： Michael KASSIOU ,  William JORGENSEN ,  Lenka MUNOZ

IPC分类号： C07D213/75 ,  C07D213/82 ,  C07D241/24 ,  C07D307/66 ,  C07D317/66

摘要： The present invention relates to new pharmaceutical agents, and to their use in the treatment of proliferative diseases, such as cancer (in particular, brain cancer).

公开(公告)号：US20130224114A1

公开(公告)日：2013-08-29

申请号：US13849658

申请日：2013-03-25

申请人： The University of Sydney

发明人： Michael KASSIOU ,  Michelle Louise JAMES ,  Christopher Andrew LUUS

IPC分类号： C07D487/04 ,  C07D207/337 ,  C07D401/04

CPC分类号： C07D487/04 ,  A61K51/0446 ,  A61K51/0455 ,  A61K51/0459 ,  C07D207/325 ,  C07D207/337 ,  C07D401/04

摘要： The present invention relates to compounds and methods for imaging translocator protein (18 kDa) (TSPO) expression in a subject. This invention also relates to compounds and methods for the treatment of neurodegenerative disorders, inflammation or anxiety in a subject.

摘要翻译： 本发明涉及在受试者中成像易位蛋白（18kDa）（TSPO）表达的化合物和方法。 本发明还涉及用于治疗受试者的神经变性疾病，炎症或焦虑症的化合物和方法。

公开(公告)号：US20210094915A1

公开(公告)日：2021-04-01

申请号：US16965398

申请日：2019-02-01

申请人： The University of Sydney

发明人： Michael KASSIOU ,  Wiiliam UORGENSEN ,  Lenka MUNOZ

IPC分类号： C07D213/75 ,  C07D317/66 ,  C07D307/66 ,  C07D213/82 ,  C07D241/24

摘要： The present invention relates to new pharmaceutical agents, and to their use in the treatment of proliferative diseases, such as cancer (in particular, brain cancer).

公开(公告)号：US20190290658A1

公开(公告)日：2019-09-26

申请号：US15738532

申请日：2016-07-06

申请人： The University of Sydney

发明人： Iain Stewart MCGREGOR ,  Michael KASSIOU ,  Michael Thomas BOWEN ,  Callum HICKS ,  William JORGENSEN

IPC分类号： A61K31/5517 ,  A61K31/553 ,  A61K31/554 ,  A61P25/22 ,  A61P25/30 ,  A61K31/4745

摘要： Disclosed herein are compounds, compositions and methods for the treatment of neurological, psychiatric disorders which are characterised by a fundamental disruption of social behaviour, and substance use disorders. In particular, disclosed herein are compounds of Formula (I), or salts or prodrugs thereof. Methods of treating or preventing neurological, psychiatric disorders and substance use disorders, using compounds of Formula (I), or salts and prodrugs are also disclosed.

公开(公告)号：US20200255475A1

公开(公告)日：2020-08-13

申请号：US16650943

申请日：2018-09-27

申请人： The University of Sydney

发明人： Michael KASSIOU ,  Damien GULLIVER ,  Tristan REEKIE ,  Timothy KATTE ,  William JORGENSEN ,  Eryn Werry

IPC分类号： C07K7/16 ,  A61P25/30

摘要： Compound of Formula I being cyclic metabolites of oxytocin. These derivatives have enhanced selectivity for the oxytocin receptor.

公开(公告)号：US20200000823A1

公开(公告)日：2020-01-02

申请号：US16439570

申请日：2019-06-12

申请人： THE UNIVERSITY OF SYDNEY

发明人： Michael KASSIOU ,  William JORGENSEN ,  Eryn WERRY ,  Tristan REEKIE ,  Michael BOWEN ,  Iain MCGREGOR

IPC分类号： A61K31/5517 ,  A61P25/00

摘要： Disclosed herein are compounds according to Formula I; a pharmaceutical composition including, consisting essentially of, or consisting of: a pharmaceutically acceptable compound of Formula I and a pharmaceutically acceptable carrier, diluent, or excipient; the use of compounds of Formula I in the preparation of a medicament; and a method including administering a pharmaceutical compositions comprising the compound of Formula I to a patient. The compounds, compositions, use, and methods are directed to the treatment of neurological, psychiatric disorders which are characterised by a fundamental disruption of social behaviour, and substance use disorders.